<GlossaryTerm id="CDR0000675317"><TermName>foretinib</TermName><TermPronunciation>(for-eh-TIH-nib)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. Foretinib blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors  need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called MET/VEGFR-2 inhibitor GSK1363089 and XL880.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000727982" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;foretinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000727981" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;foretinib&quot;" language="es" id="_4"/><SpanishTermName>foretinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del cáncer.    El foretinib bloquea las enzimas que participan en la formación y diseminación de células tumorales. También es posible que evite la formación de los vasos sanguíneos nuevos que los tumores necesitan para crecer. Es un tipo de antiangiogénico y de inhibidor de tirosina–cinasas. También se llama inhibidor GSK1363089 de MET y VEGFR-2 y XL880.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-06-09</DateFirstPublished><DateLastModified>2010-06-09</DateLastModified></GlossaryTerm>
